Shares of Allergan PLC (NYSE:AGN) dropped 2.8% during trading on Wednesday after Mizuho lowered their price target on the stock from $305.00 to $299.00. Mizuho currently has a buy rating on the stock. Allergan PLC traded as low as $229.33 and last traded at $231.30, with a volume of 3,369,448 shares traded. The stock had previously closed at $237.95.

Several other brokerages have also commented on AGN. Bank of America Corp. set a $294.00 price objective on shares of Allergan PLC and gave the stock a “buy” rating in a research report on Tuesday, September 20th. Piper Jaffray Cos. reiterated a “hold” rating and issued a $236.00 target price on shares of Allergan PLC in a research note on Saturday, June 18th. Credit Suisse Group AG set a $322.00 target price on shares of Allergan PLC and gave the stock a “hold” rating in a research note on Wednesday, August 3rd. Leerink Swann reiterated a “buy” rating on shares of Allergan PLC in a research note on Thursday, June 30th. Finally, Goldman Sachs Group Inc. reiterated a “buy” rating on shares of Allergan PLC in a research note on Monday, September 12th. Six analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Allergan PLC currently has a consensus rating of “Buy” and a consensus price target of $302.23.

A number of large investors have recently bought and sold shares of the stock. Vanguard Group Inc. raised its stake in Allergan PLC by 1.9% in the second quarter. Vanguard Group Inc. now owns 24,362,503 shares of the company’s stock worth $5,629,931,000 after buying an additional 445,456 shares in the last quarter. Jackson Square Partners LLC raised its stake in Allergan PLC by 5.7% in the second quarter. Jackson Square Partners LLC now owns 3,840,160 shares of the company’s stock worth $1,004,656,000 after buying an additional 205,701 shares in the last quarter. Geode Capital Management LLC raised its stake in Allergan PLC by 1.9% in the first quarter. Geode Capital Management LLC now owns 3,238,971 shares of the company’s stock worth $866,405,000 after buying an additional 60,819 shares in the last quarter. UBS Asset Management Americas Inc. raised its stake in Allergan PLC by 7.7% in the first quarter. UBS Asset Management Americas Inc. now owns 3,232,147 shares of the company’s stock worth $866,313,000 after buying an additional 231,603 shares in the last quarter. Finally, General Electric Co. raised its stake in Allergan PLC by 13.7% in the second quarter. General Electric Co. now owns 2,676,658 shares of the company’s stock worth $618,549,000 after buying an additional 322,108 shares in the last quarter. Institutional investors own 85.19% of the company’s stock.

The stock has a market capitalization of $91.79 billion, a P/E ratio of 22.07 and a beta of 0.81. The company’s 50 day moving average price is $239.23 and its 200-day moving average price is $238.48.

Allergan PLC (NYSE:AGN) last announced its quarterly earnings data on Monday, August 8th. The company reported $3.35 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.34 by $0.01. Allergan PLC had a net margin of 28.06% and a return on equity of 7.67%. The business earned $3.68 billion during the quarter, compared to analyst estimates of $4.10 billion. During the same period last year, the firm posted $4.41 EPS. The company’s revenue was up 1.0% on a year-over-year basis. Equities research analysts anticipate that Allergan PLC will post $14.00 earnings per share for the current fiscal year.

Allergan PLC Company Profile

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

5 Day Chart for NYSE:AGN

Receive News & Stock Ratings for Allergan PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC and related stocks with our FREE daily email newsletter.